Recent Quotes (30 days)

You have no recent quotes
chg | %

Takeda Pharmaceutical Co Ltd news

   Watch this stock
Showing stories 1 - 10 of about 125   

Articles published

4502 5,975.00
price chart
Takeda Pharmaceutical Co Ltd (ADR) Plans To Offer $2.2 Billion To Settle Actos ...
Takeda Pharmaceutical Co Ltd (ADR) (OTCMKTS:TKPYY) has, as per anonymous sources, expressed its willingness to put down over $2.2 billion in an attempt to settle claims that the company deliberately withheld information about the risk of cancer from ...
Drugmaker Takeda may settle Actos suits for $2.2 billion  The Japan Times
Japan's Takeda Pharmaceutical offers $2.2 billion to settle US drug lawsuits  Economic Times
Moody's: Takeda's rating not immediately impacted by ACTOS settlement ...
Tokyo, May 01, 2015 -- Moody's Japan K.K. says that the A1 issuer and senior unsecured debt ratings as well as (P)A1 shelf registration of Takeda Pharmaceutical Company Limited ("Takeda") will not be immediately impacted following its 28 April 2015 (U ...
Takeda Announces First Patient Enrolled in Global Phase 3 Study of Ixazomib as ...
CAMBRIDGE, Mass. & OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that the first patient has been enrolled in the Phase 3 TOURMALINE-MM4 study of investigational oral ixazomib.
Takeda to take $2.7 bln charge to settle Actos cases
April 28 Takeda Pharmaceutical Co Ltd and its Takeda Pharmaceuticals U.S.A. Inc unit said on Tuesday they reached a $2.4 billion agreement to settle the majority of claims involving the diabetes drug Actos.
Japan's Takeda Agrees To $2.4B Settlement In Diabetes Drug Actos Lawsuit ...  International Business Times
Takeda Said Ready to Pay $2.3 Billion to Settle Actos Cases  Bloomberg
Takeda Announces Appointment of New President of U.S. Business Unit
DEERFIELD, Ill., April 13, 2015 /PRNewswire/ -- Takeda Pharmaceutical Company Limited ("Takeda"), and Takeda's wholly-owned subsidiary, Takeda Pharmaceuticals U.S.
Takeda Pharmaceutical Co Rating Reiterated by Zacks (TKPYY)
Zacks' analyst wrote, “Takeda Pharmaceutical Company Limited operates as a research-based pharmaceutical company, engaged in manufacturing, marketing, and importing/exporting pharmaceutical drugs.
Immunogen (IMGN), Takeda Enter Licensing Agreement Covering ADC ...
Takeda Pharmaceutical Company Limited and ImmunoGen, Inc. (Nasdaq: IMGN) announced that Takeda has licensed exclusive rights to use ImmunoGen's ADC technology - including ImmunoGen's new DNA-acting IGN payload agents - to develop and ...
Takeda licenses ImmunoGen's ADC technology to develop cancer therapeutics  Seeking Alpha (registration)
ICYMI: Pharmaceutical Stocks Are Moving Big On Monday  Benzinga
Takeda Pharmaceuticals and Orexigen Therapeutics Announce Termination of ...
DEERFIELD, IL and SAN DIEGO, May 12, 2015 /PRNewswire/ -- Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Development Center Americas, Inc. (Takeda) and Orexigen Therapeutics, Inc. (Nasdaq: OREX) (Orexigen) ...
Orexigen Finally Pulls Plug On Cardiovascular Contrave Study  Tech Times
UPDATE 1-Orexigen says obesity drug safety trial terminated  Reuters
Sumitomo Dainippon Pharma Co. Ltd. and Takeda Pharmaceutical Company ...
Sumitomo Dainippon Pharma Co. Ltd. and Takeda Pharmaceutical Company Limited Announce Decision to Terminate Their Agreement for the Joint Development and Exclusive Commercialization of Latuda� (lurasidone) - an Atypical Antipsychotic Agent, ...
Penny Stock's Buzzers: Takeda Pharmaceutical Co Ltd (TKPYY), American ...
Manhattan, NY- May 18, 2015 - (Techsonian) –Takeda Pharmaceutical Co Ltd (ADR) (TKPYY) reported top line outcome in line with guidance, with underlying growth of +2.8% EPS affected by one-time charges in FY2014 back to profitable growth from ...